GeneCopoeia Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus

Saturday, 01 August, 2020 | Supplied by: United Bioresearch Products Pty Ltd

GeneCopoeia Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus

GeneCopoeia’s Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus products are designed to produce a specially packaged variant of standard lentivirus that replaces VSV-G envelope glycoprotein with the Spike (S) protein.

The company’s spike-pseudotyped lentivirus can be used for several applications, such as: vaccine development for the SARS-CoV-2 virus; studying the efficacy and mechanism of neutralising antibodies against the SARS-CoV-2 virus; development of antiviral therapeutic agents; and studying the mechanism of virus-receptor interaction.

In addition to lentiviral particles, GeneCopoeia also offers a SARS-CoV-2 Spike Protein Pseudotyped Lentivirus Particle Kit that includes all required reagents: Lentifect SARS-CoV-2 Spike protein-pseudotyped lentiviral particles; Lentifect Standard VSV-G lentiviral particles; and the company’s ACE2-expressing HEK293T cell line.

For more information: https://www.genecopoeia.com/product/lentifect-sars-cov-2-spike-pseudotyped-lentivirus/.

Online: www.unitedbioresearch.com.au
Phone: 02 4575 0309
Related Products

Cayman Chemical Bio-Active Lipid I Screening Library (96-Well)

Cayman Chemical's Bio-Active Lipid I Screening Library consists of 13 plates and contains...

Echelon Biosciences ionisable lipids

Echelon Biosciences' ionisable lipids are the key components of lipid nanoparticles (LNPs)...

BioStatus CyTRAK Orange fluorescent dye

BioStatus's CyTRAK Orange is a novel fluorescent dye that preferentially stains the nucleus...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd